Tel Aviv, July 22, 2025 - SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification from The Nasdaq Stock Market LLC on July 18, 2025, confirming that its ordinary shares maintained a closing bid price of at least $1.00 for 10 consecutive business days. This compliance resolves the prior bid price deficiency issue, and Nasdaq now considers the matter closed.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。